Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

​Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-GI3, for its candidate Ivonescimab.

​Ivonescimab is a novel biospecific antibody that combines with chemotherapy in patients with unresectable metastatic colorectal cancer. The phase 3 trials will compare ivonescimab plus chemotherapy with bevacizumab plus chemotherapy as first-line therapy for patients with CRC. Management noted that the trial is global and they aim to enroll around 600 patients. Trial sites in the United States are expected to start soon.

​Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that is focused on developing therapies mainly for cancer treatment.

While we acknowledge the potential of SMMT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SMMT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.